0001181431-13-033369.txt : 20130607 0001181431-13-033369.hdr.sgml : 20130607 20130607060140 ACCESSION NUMBER: 0001181431-13-033369 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130604 FILED AS OF DATE: 20130607 DATE AS OF CHANGE: 20130607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8424 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martignetti Anthony CENTRAL INDEX KEY: 0001574697 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 13898847 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 rrd382736.xml FORM 4 X0306 4 2013-06-04 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001574697 Martignetti Anthony 215 FIRST STREET, SUITE 7 CAMBRIDGE MA 02412 0 0 0 1 See Remarks Incentive Stock Option (right to buy) 34.9200 2013-06-04 4 A 0 4901 0 A 2023-06-04 Common Stock 4901 4901 D Non-Qualified Stock Option (right to buy 34.9200 2013-06-04 4 A 0 99 0 A 2023-06-04 Common Stock 99 99 D This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant. On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders. Dir Finance - Chief Accounting Officer & Corporate Controller By: David Tyronne Howton For: Anthony Martignetti 2013-06-06